<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26837471</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial.</ArticleTitle><Pagination><StartPage>922</StartPage><EndPage>930</EndPage><MedlinePgn>922-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1115934</ELocationID><Abstract><AbstractText>Human enterovirus 71 (EV71) is a causative agent of hand, foot, and mouth disease (HFMD). In a previous phase III trial in children, a human diploid cell-based inactivated EV71 vaccine elicited EV71 specific immune responses and protection against EV71 associated HFMD. This study aimed to assess the factors influencing the severity of adverse events observed in this previous trial. This was a randomized, double-blinded, placebo-controlled, phase III clinical trial of a human diploid vaccine carried out in 12,000 children in Guangxi Zhuang Autonomous Region, China (ClinicalTrials.gov: NCT01569581). Solicited events were recorded for 7&#xa0;days and unsolicited events were reported for 28&#xa0;days after each injection. Age trend analysis of adverse reaction was conducted in each treatment group. Multiple logistic regression models were built to identify factors influencing the severity of adverse reactions. Fewer solicited adverse reactions were observed in older participants within the first 7&#xa0;days after vaccination (P &lt; 0.0001), except local pain and pruritus. More severe adverse reactions were observed after the initial injection than after the booster injection. Serious cold or respiratory tract infections (RTI) were observed more often in children aged 6-36 months than in older children. Only the severity of local swelling was associated with body mass index. Children with throat discomfort before injection had a higher risk of serious cold or RTI. These results indicated that the human diploid cell-based vaccine achieved a satisfactory safety profile.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>a Department of Health Statistics , Faculty of Preventative Medicine, Fourth Military Medical University , Xi'an , Shaanxi , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Yujia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>a Department of Health Statistics , Faculty of Preventative Medicine, Fourth Military Medical University , Xi'an , Shaanxi , China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Department of Public Health , Weifang Medical College , Weifang , Shandong , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>a Department of Health Statistics , Faculty of Preventative Medicine, Fourth Military Medical University , Xi'an , Shaanxi , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chanjuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>a Department of Health Statistics , Faculty of Preventative Medicine, Fourth Military Medical University , Xi'an , Shaanxi , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>a Department of Health Statistics , Faculty of Preventative Medicine, Fourth Military Medical University , Xi'an , Shaanxi , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Jielai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a Department of Health Statistics , Faculty of Preventative Medicine, Fourth Military Medical University , Xi'an , Shaanxi , China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01569581</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003139" MajorTopicYN="N">Common Cold</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004171" MajorTopicYN="N">Diploidy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">hand-foot-mouth disease</Keyword><Keyword MajorTopicYN="N">safety analysis</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26837471</ArticleId><ArticleId IdType="pmc">PMC4962949</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1115934</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xiao G, Hu Y, Yu S, Ma J. Epidemiology of hand, foot and mouth disease in children aged 5&#xa0;years in China, 2008&#x2013;2011. Dis Surveill 2012; 27:932-6.</Citation></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9:1097-105; PMID:20965438; http://dx.doi.org/10.1016/S1474-4422(10)70209-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 1998; 352:1391; PMID:9802304; http://dx.doi.org/10.1016/S0140-6736(05)60789-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)60789-1</ArticleId><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, et&#xa0;al.. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999; 354:1682-6; PMID:10568570; http://dx.doi.org/10.1016/S0140-6736(99)04434-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, et&#xa0;al.. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum Vaccin Immunother 2014; 10:2885-95; PMID:25483672; http://dx.doi.org/10.4161/hv.29823</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29823</ArticleId><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="pubmed">25483672</ArticleId></ArticleIdList></Reference><Reference><Citation>De W, Changwen K, Wei L, Monagin C, Jin Y, Cong M, Hanri Z, Jun S. A large outbreak of hand, foot, and mouth disease caused by EV71 and CAV16 in Guangdong, China, 2009. Arch Virol 2011; 156:945-53; PMID:21305327; http://dx.doi.org/10.1007/s00705-011-0929-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-0929-8</ArticleId><ArticleId IdType="pubmed">21305327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M. Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect 2000; 33:205-16; PMID:11269363</Citation><ArticleIdList><ArticleId IdType="pubmed">11269363</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Report on the Hand, Foot and Mouth Disease Outbreak in Fuyang City, Anhui Province and the Prevention and Control in China. 2008:1-25.</Citation></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012; 30:3295-303; PMID:22426327; http://dx.doi.org/10.1016/j.vaccine.2012.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines. Clin Infect Dis 2015; 60:797-803; PMID:25352588; http://dx.doi.org/10.1093/cid/ciu852</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26:91-107; PMID:12007645; http://dx.doi.org/10.1111/j.1574-6976.2002.tb00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect 2010; 12:505-10; PMID:20348010; http://dx.doi.org/10.1016/j.micinf.2010.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, et&#xa0;al.. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381:1037-45; PMID:23352749; http://dx.doi.org/10.1016/S0140-6736(12)61764-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, Huo X, Zhou J, Wu Y, Yan D, et&#xa0;al.. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011; 6:e25662; PMID:21980521; http://dx.doi.org/10.1371/journal.pone.0025662</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, Zhou J, Shi J, Zhao Y, Wang X, et&#xa0;al.. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14&#xa0;years. PLoS One 2013; 8:e56341; PMID:23441179; http://dx.doi.org/10.1371/journal.pone.0056341</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056341</ArticleId><ArticleId IdType="pmc">PMC3575343</ArticleId><ArticleId IdType="pubmed">23441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun LM, Zheng HY, Zheng HZ, Guo X, He JF, Guan DW, Kang M, Liu Z, Ke CW, Li JS, et&#xa0;al.. An enterovirus 71 epidemic in Guangdong Province of China, 2008: epidemiological, clinical, and virogenic manifestations. Jpn J Infect Dis 2011; 64:13-8; PMID:21266750</Citation><ArticleIdList><ArticleId IdType="pubmed">21266750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML. The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol 2011; 37:313-27; PMID:21651436; http://dx.doi.org/10.3109/1040841X.2011.580723</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1040841X.2011.580723</ArticleId><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung YA, Hung CT, Liu YC, Shih SR. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther 2014; 14:1455-64; PMID:24989170; http://dx.doi.org/10.1517/14712598.2014.935330</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2014.935330</ArticleId><ArticleId IdType="pubmed">24989170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et&#xa0;al.. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024-32; PMID:23726161; http://dx.doi.org/10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, et&#xa0;al.. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. J Infect Dis 2014; 209:46-55; PMID:23922377; http://dx.doi.org/10.1093/infdis/jit429</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Wang J. EV71 vaccine, an invaluable gift for children. Clin Transl Immunology 2014; 3:e28; PMID:25505956; http://dx.doi.org/10.1038/cti.2014.24</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2014.24</ArticleId><ArticleId IdType="pmc">PMC4237031</ArticleId><ArticleId IdType="pubmed">25505956</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 2013; 9:1701-5; PMID:23744508; http://dx.doi.org/10.4161/hv.24949</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Jee YM, Cheon DS, Kim K, Cho JH, Chung YS, Lee J, Lee SH, Park KS, Lee JH, Kim EC, et&#xa0;al.. Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. Arch Virol 2003; 148:1735-46; PMID:14505086; http://dx.doi.org/10.1007/s00705-003-0133-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-003-0133-6</ArticleId><ArticleId IdType="pubmed">14505086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwa SH, Lee YA, Brewoo JN, Partidos CD, Osorio JE, Santangelo JD. Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine. PLoS Negl Trop Dis 2013; 7:e2538; PMID:24244774; http://dx.doi.org/10.1371/journal.pntd.0002538</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002538</ArticleId><ArticleId IdType="pmc">PMC3820736</ArticleId><ArticleId IdType="pubmed">24244774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, et&#xa0;al.. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013; 31:2471-6; PMID:23541623; http://dx.doi.org/10.1016/j.vaccine.2013.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.015</ArticleId><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chow YH, Chong P, Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine 2014; 32:6177-82; PMID:25218294; http://dx.doi.org/10.1016/j.vaccine.2014.08.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.064</ArticleId><ArticleId IdType="pubmed">25218294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun KW, Lee HJ, Kang JH, Eun BW, Kim YJ, Kim KH, Kim NH, Hong YJ, Kim DH, Kim HM, et&#xa0;al.. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC(R)) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial. BMC Infect Dis 2015; 15:7; PMID:25567119; http://dx.doi.org/10.1186/s12879-014-0744-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-014-0744-4</ArticleId><ArticleId IdType="pmc">PMC4296691</ArticleId><ArticleId IdType="pubmed">25567119</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona Martinez A, Salamanca de la Cueva I, Boutet P, Vanden Abeele C, Smolenov I, Devaster JM. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. Hum Vaccin Immunother 2014; 10:1959-68; PMID:25424805; http://dx.doi.org/10.4161/hv.28743</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28743</ArticleId><ArticleId IdType="pmc">PMC4186022</ArticleId><ArticleId IdType="pubmed">25424805</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, Wu CL, Huang JL, Fung CP, Hsieh SM, et&#xa0;al.. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013; 8:e79783; PMID:24278177; http://dx.doi.org/10.1371/journal.pone.0079783</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials. Expert Rev Vaccines 2014; 13:609-18; PMID:24621093; http://dx.doi.org/10.1586/14760584.2014.897617</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.897617</ArticleId><ArticleId IdType="pubmed">24621093</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Meng FY, Mao Q, Li JX, Wang H, Liang ZL, Zhang YT, Gao F, Chen QH, Hu Y, et&#xa0;al.. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother 2014; 10:1366-72; PMID:24633366; http://dx.doi.org/10.4161/hv.28397</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28397</ArticleId><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="pubmed">24633366</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et&#xa0;al.. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370:829-37; PMID:24571755; http://dx.doi.org/10.1056/NEJMoa1303224</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et&#xa0;al.. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370:818-28; PMID:24571754; http://dx.doi.org/10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et&#xa0;al.. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013; 8:e54451; PMID:23372725; http://dx.doi.org/10.1371/journal.pone.0054451</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma SH, Liu JS, Wang JJ, Shi HJ, Yang HJ, Chen JY, Liu LD, Li QH. Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Fuyang, China, during 2008. Virologica Sinica 2009; 24:162-70; http://dx.doi.org/10.1007/s12250-009-3033-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-009-3033-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, et&#xa0;al.. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 312:1420-8; PMID:25291578; http://dx.doi.org/10.1001/jama.2014.12609</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.12609</ArticleId><ArticleId IdType="pubmed">25291578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocki J, Brzostek J, Szymanski H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Krolikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, et&#xa0;al.. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naive to pneumococcal vaccination. Vaccine 2015; 33:1719-25; PMID:25698485; http://dx.doi.org/10.1016/j.vaccine.2015.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.02.005</ArticleId><ArticleId IdType="pubmed">25698485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan T, Richmond PC, McVernon J, Skeljo MV, Hartel GF, Bennet J, Basser RL. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir Viruses 2009; 3:315-25; PMID:19903213; http://dx.doi.org/10.1111/j.1750-2659.2009.00108.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-2659.2009.00108.x</ArticleId><ArticleId IdType="pmc">PMC4941394</ArticleId><ArticleId IdType="pubmed">19903213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert SB, Chuk LM, Nissen MD, Nolan TM, McVernon J, Booy R, Heron L, Richmond PC, Walls T, Marshall HS, et&#xa0;al.. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. Influenza Other Respir Viruses 2013; 7:676-85; PMID:23551933; http://dx.doi.org/10.1111/irv.12107</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12107</ArticleId><ArticleId IdType="pmc">PMC5781200</ArticleId><ArticleId IdType="pubmed">23551933</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenyu W, Jingxin L, Zhenglun L, Xiuling L, Qunying M, Fanyue M, Hua W, Yuntao Z, Fan G, Qinghua C, et&#xa0;al.. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial. J Infect Dis 2014; 210:1073-82; PMID:24625805; http://dx.doi.org/10.1093/infdis/jiu113</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu113</ArticleId><ArticleId IdType="pubmed">24625805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, Chang L, Liang ZL, Xia JL, Dai QG, Hu YL, et&#xa0;al.. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013; 20:1805-11; PMID:24108780; http://dx.doi.org/10.1128/CVI.00491-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00491-13</ArticleId><ArticleId IdType="pmc">PMC3889509</ArticleId><ArticleId IdType="pubmed">24108780</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Yin H, An Z, Feng Z. Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine 2015; 33:1107-12; PMID:25444807; http://dx.doi.org/10.1016/j.vaccine.2014.10.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.10.081</ArticleId><ArticleId IdType="pubmed">25444807</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>